Cns Gene Therapy
Cns Gene Therapy - Related Videos
13:12
Efficient Gene Delivery into Multiple CNS Territories Using In Utero Electroporation
0 Views •
Cited by 31 •
2011
In utero electroporation allows for rapid gene delivery in a spatially- and temporally-controlled manner in the developing central nervous system (CNS). Here we describe a highly adaptable in utero electroporation protocol that can be used to deliver expression constructs into multiple embryonic CNS domains, including the telencephalon, diencephalon and retina.
01:22
Gene Therapy
0 Views •
2021
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:22
Gene Therapy
0 Views •
2026
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
06:29
Dissection of Larval CNS in Drosophila Melanogaster
0 Views •
Cited by 18 •
2006
In this article we demonstrate how to dissect the central nervous system from third instar Drosophila larvae.
07:32
Assessment of Vascular Regeneration in the CNS Using the Mouse Retina
0 Views •
Cited by 7 •
2014
The rodent retina has long been recognized as an accessible window to the brain. In this technical paper we provide a protocol that employs the mouse model of oxygen-induced retinopathy to study the mechanisms that lead to failure of vascular regeneration within the central nervous system after ischemic injury. The described system can also be harnessed to explore strategies to promote regrowth of functional blood vessels within the retina and CNS.
FAQs
The introduced genetic material can serve several purposes: replacing a missing cellular function, reducing expression of a harmful gene, or enabling neurons or glial cells to produce a therapeutic protein. These mechanisms address different disease features, so the intended genetic effect must match whether pathology results from loss of function, harmful expression, or insufficient therapeutic activity.
Neurons and glial cells are the principal nervous-system cell types identified as targets for delivered genetic material. Reaching the appropriate population determines where the therapeutic effect occurs and whether the introduced material can influence disease-related functions. This cellular targeting is especially relevant when researchers study inherited or neurodegenerative disorders affecting specific components of brain or spinal cord tissue.
Viral and nonviral systems provide alternative ways to transport genetic material into the central nervous system. The choice affects how the material is delivered to nervous tissue and how effectively it reaches intended cells. Because the blood-brain barrier restricts access, researchers must consider delivery-system performance together with the administration route and the desired distribution within the brain or spinal cord.
The blood-brain barrier limits movement of therapeutic material into nervous tissue, making ordinary access insufficient for many treatment strategies. Consequently, development may require specialized vectors or administration routes designed to improve distribution through the brain or spinal cord. Better distribution can increase the likelihood that the genetic material reaches relevant neurons or glial cells across the intended treatment area.
A development workflow begins by identifying the disease-related genetic objective, such as replacing a missing function, reducing harmful gene expression, or supporting therapeutic-protein production. Researchers then select a viral or nonviral delivery system, determine how to administer it past the access limitations of the blood-brain barrier, and evaluate whether distribution reaches the relevant central nervous system tissue.
CNS gene therapy is particularly relevant for inherited and neurodegenerative disorders that remain difficult to manage with conventional drugs. It may be investigated when a durable genetic effect is desirable, such as restoring a missing function or altering harmful gene expression. Research therefore focuses on whether delivery can produce a sustained therapeutic benefit in the brain or spinal cord.